CLINICAL TRIALS PROFILE FOR NITAZOXANIDE

All Clinical Trials for nitazoxanide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001081 ↗	A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To determine the frequency of complete, marked, and partial clinical responses in patients with cryptosporidiosis treated with 6 weeks of NTZ versus 21 days of placebo. To determine the safety of NTZ in subjects with cryptosporidiosis. There is no proven therapy for cryptosporidiosis in persons with AIDS. Nitazoxanide appears to be a good candidate drug for further evaluation because of its effectiveness in preclinical models, the data from early clinical trials and its safety profile. Cooperation between clinical researchers and basic scientists in clinical trials of agents for HIV infection and its complications is a high priority for the ACTG, the NIAID, and the NIH. Thus, it is important to design a clinical trial of NTZ that includes cooperation with basic scientists.
NCT00002158 ↗	A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis	Unknown status	Romark Laboratories L.C.	N/A	1969-12-31	The purpose of this study is to see if nitazoxanide (NTZ) can be used to treat AIDS patients suffering from cryptosporidiosis (diarrhea caused by the parasite Cryptosporidium).
NCT00002444 ↗	A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea	Completed	Unimed Pharmaceuticals	Phase 1	1995-10-01	To determine the pharmacokinetics profile of single doses of nitazoxanide (NTZ) in patients with AIDS-related cryptosporidial diarrhea. To determine steady state concentrations of NTZ following repeated dosing. To assess the safety and efficacy of 4 dose levels of NTZ in these patients. Cryptosporidial enterocolitis in AIDS patients is frequently chronic and severe, contributing substantially to morbidity, mortality, and health care costs in this population. NTZ exhibits antimicrobial activity that may extend to Cryptosporidial infection.
NCT00004986 ↗	Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients	Terminated	Romark Laboratories L.C.	Phase 3	2000-02-01	The purpose of this study is to see if it is safe and effective to treat cryptosporidiosis in AIDS patients with nitazoxanide.
NCT00055107 ↗	Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1/Phase 2	1969-12-31	Cryptosporidium parvum (C. parvum) is a parasite that can cause chronic diarrhea and is a significant problem for HIV infected children in developing countries. C. parvum infection can be treated with the drug nitazoxanide (NTZ). However, NTZ has not been tested in HIV infected children. The purpose of this study is to test the safety of NTZ in HIV infected children who have chronic diarrhea caused by C. parvum. Study hypothesis: Twice-daily NTZ is safe and well tolerated in HIV infected infants, children, and adolescents with chronic diarrhea caused by C. parvum infection.

Clinical Trial Conditions for nitazoxanide

Condition Name

Condition Name for nitazoxanide
Intervention	Trials
Covid19	13
COVID-19	12
Chronic Hepatitis c	8
Influenza	6

Condition MeSH

Condition MeSH for nitazoxanide
Intervention	Trials
COVID-19	26
Hepatitis	14
Hepatitis A	13
Hepatitis C	13

Clinical Trial Locations for nitazoxanide

Trials by Country

Trials by Country for nitazoxanide
Location	Trials
United States	178
Egypt	32
Australia	11
South Africa	7
Mexico	6

Trials by US State

Trials by US State for nitazoxanide
Location	Trials
Florida	16
New York	15
Texas	12
California	11
Georgia	9

Clinical Trial Progress for nitazoxanide

Clinical Trial Phase

Clinical Trial Phase for nitazoxanide
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE2	1

Clinical Trial Status

Clinical Trial Status for nitazoxanide
Clinical Trial Phase	Trials
Completed	48
Recruiting	23
Not yet recruiting	11

Clinical Trial Sponsors for nitazoxanide

Sponsor Name

Sponsor Name for nitazoxanide
Sponsor	Trials
Romark Laboratories L.C.	29
Tanta University	12
National Institute of Allergy and Infectious Diseases (NIAID)	6

Sponsor Type

Sponsor Type for nitazoxanide
Sponsor	Trials
Other	147
Industry	51
NIH	9

Nitazoxanide Market Analysis and Financial Projection

Last updated: February 8, 2026

What is Nitazoxanide and Why Is It Undergoing Clinical and Market Analysis?

Nitazoxanide is an antiparasitic and antiviral agent approved by the U.S. Food and Drug Administration (FDA) in 2002 for treating protozoal infections, primarily cryptosporidiosis and giardiasis. Its broad-spectrum activity against various infectious agents has prompted renewed interest, particularly in viral indications such as hepatitis B and C, influenza, and emerging pathogens like coronaviruses.

What Are the Latest Clinical Trial Developments for Nitazoxanide?

Current Clinical Trials Landscape

As of 2023, several clinical trials are ongoing or completed assessing Nitazoxanide's efficacy against viral infections, including:

• COVID-19: Multiple Phase II/III trials explored Nitazoxanide as an oral antiviral candidate. Notably, a trial registered under NCT04576199 evaluated its efficacy in mild to moderate COVID-19 patients. Results published in 2022 indicated reduced viral load and symptom duration compared to standard care. No significant safety concerns arose.

• Hepatitis B and C: Phase II trials assessed Nitazoxanide combined with other antivirals. Efficacy varied, with some studies reporting modest viral suppression, but no major breakthrough led to regulatory approval.

• Influenza: Small-scale studies in 2020 suggested potential benefit, but lacked robust evidence for widespread adoption.

Trial Outcomes and Gaps

• Efficacy Variability: While promising in certain viral infections, clinical trial results are inconsistent, often due to small sample sizes and differing endpoints.

• Safety Profile: Generally well tolerated, with adverse events comparable to placebo. Liver enzyme elevations and gastrointestinal symptoms are most common.

• Regulatory Status: No major regulatory revisions or new approvals have arisen solely based on recent trial data.

Future Trial Considerations

• Larger, randomized controlled trials are necessary to confirm efficacy, especially in viral diseases with high unmet needs.
• Combination therapy studies could expand indications.

How Is the Market for Nitazoxanide Currently Structured?

Market Size and Sales Data

• Market Value: Estimated at roughly USD 250 million globally in 2022, primarily driven by treatment of parasitic infections in developing countries.

• Pricing and Revenue: Sold at low cost as a generic drug; annual sales in major markets (U.S., EU, Asia) are constrained by generic competition.

• Sales Composition: Roughly 70% from antiparasitic indications, 30% from off-label/clinical trial use for viral infections.

Leading Manufacturers and Distribution

• Manufacturers: Originally developed by Romark Laboratories, now marketed by multiple generic producers worldwide.

• Distribution: Widely available in low- to middle-income countries; limited commercial promotion for off-label viral indications.

What Is the Market Projection for Nitazoxanide?

Short-Term Outlook (Next 2 Years)

• Demand Drivers: Driven by ongoing COVID-19 research, the potential for new viral indications, and existing parasitic uses.

• Market Growth Rate: Expected to grow at 3-5% annually, mainly from regions expanding access to antiparasitic treatments.

• Regulatory Impact: Additional approvals for new indications could catalyze market expansion; currently, no substantial approvals are anticipated without robust clinical evidence.

Medium to Long-Term Outlook (3–10 Years)

• Potential for Growth: Dependent on clinical trial success, especially for respiratory and viral indications.

• Market Expansion Factors:

  • Research confirming efficacy against emerging viruses.
  • Competitive landscape shifts toward combination therapies.
  • Patent status evolution: As a generic, market entry barriers are minimal.

• Forecasted Market Size: Could reach USD 500 million if new indications are approved and adopted, especially in regions prioritizing affordable antiviral options.

What Are Challenges and Opportunities?

Challenges

• Lack of large-scale positive trial data limits expansion beyond parasitic diseases.
• Competition from other antivirals, especially in COVID-19 and hepatitis treatments.
• Regulatory hurdles for off-label viral indications.

Opportunities

• Potential as an affordable antiviral for emerging infectious diseases.
• Interest in combination regimens for resistant infections.
• Expanding access in endemic regions.

Key Takeaways

• Nitazoxanide has a well-established safety profile for parasitic infections with ongoing evaluation for antiviral uses.
• Recent clinical trial results for COVID-19 show modest benefits, but larger trials are needed for regulatory approval.
• The current global market is modest, primarily serving parasitic indications, with growth prospects tied to new approvals and research success.
• Market expansion depends on clinical validation of efficacy, especially for viral infections.
• Patent expiration of original formulations and generic availability hinge on regulatory decisions and new indication approvals.

FAQs

1. Is Nitazoxanide approved for COVID-19 treatment?
No. While studies indicate potential benefits, it has not received formal approval for COVID-19 outside clinical trials.

2. What indications currently drive Nitazoxanide sales?
Primarily parasitic infections such as cryptosporidiosis and giardiasis in developing countries.

3. Have recent trials established Nitazoxanide as a standard antiviral therapy?
No. Evidence remains preliminary; it is not officially endorsed as standard for viral diseases.

4. Could patent issues affect Nitazoxanide market growth?
As a generic, patent expirations have reduced barriers to widespread manufacturing, but new formulations or indications could influence this dynamic.

5. What regions are most likely to see growth in Nitazoxanide usage?
Developing countries, due to high parasitic infection burden, with potential growth in regions where new antiviral indications are approved.

---

References

[1] FDA. "FDA Approval for Nitazoxanide," 2002.
[2] ClinicalTrials.gov. "Nitazoxanide COVID-19 Trials," 2022-2023.
[3] MarketWatch. "Global Nitazoxanide Market Size and Forecast," 2022.
[4] Romark Laboratories. "Historical Data on Nitazoxanide," 2002.